Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.

Christopher Sweeney,Ivor John Percent,Sunil Babu,Jennifer Cultrera,Bryan Mehlhaff,Oscar B. Goodman,David L. Morris,Ian D. Schnadig,Costantine Albany,Neal D. Shore,Paul Sieber,Susan C. Guba,Minmin Wang,Suhyun Kang,Volker Wacheck,Gregory P. Donoho,Anna M. Szpurka,Sophie Callies,Boris Lin,Johanna C. Bendell

Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.

2019

5009Background: Preclinical and phase 1 results suggest PI3K/mTOR pathway inhibition may enhance androgen receptor inhibition. We report the results of a double-blind, placebo-controlled, randomize...

Keywords:

Placebo
Castration
Prostate cancer
Abiraterone
Pathology
Oncology
Enzalutamide
Internal medicine
Medicine
castration resistant
Androgen receptor
PI3K/AKT/mTOR pathway
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations